Solid Biosciences Inc.
Solid Biosciences Inc. (Nasdaq: SLDB) is a life sciences company developing gene therapy candidates for rare neuromuscular and cardiac diseases. Its pipeline includes SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and… From the company’s description.
In fiscal 2025, Solid Biosciences Inc. reported a net loss of $174.32M. Operations used $156.29M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Solid Biosciences Inc. does
In the company’s own words
Solid Biosciences Inc. (Nasdaq: SLDB) is a life sciences company developing gene therapy candidates for rare neuromuscular and cardiac diseases. Its pipeline includes SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and candidates for inherited cardiomyopathies, including SGT-601 for TNNT2-mediated dilated cardiomyopathy. The company’s programs use gene transfer to deliver functional genetic material to patients’ cells, and it also develops platform technologies such as novel capsids and genetic regulators. Its clinical-stage candidates are being evaluated in trials, while other programs remain in preclinical development or discovery; it has no product sales. Solid also licenses its POLARIS-101 capsid to companies, institutions and academic laboratories pursuing neuromuscular and cardiac disease research, with more than 50 agreements including licenses executed. The company was organized in 2013 as SOLID Ventures Management, LLC and converted to a Delaware corporation in 2018. Its website is https://www.solidbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CHARLESTOWN, MA
- Fiscal year end
- December
- CIK
- 1707502
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Solid Biosciences Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Solid Biosciences Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Solid Biosciences Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Solid Biosciences Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Solid Biosciences Inc.'s last four quarterly filings that the numbers alone won't show?”